International Journal of Hematology

, Volume 90, Issue 1, pp 1–5

Non-A type nucleophosmin 1 gene mutation predicts poor clinical outcome in de novo adult acute myeloid leukemia: differential clinical importance of NPM1 mutation according to subtype

  • Youngil Koh
  • Juwon Park
  • Eun-Kyung Bae
  • Kwang-Sung Ahn
  • Inho Kim
  • Soo-Mee Bang
  • Jae-Hoon Lee
  • Sung-Soo Yoon
  • Dong Soon Lee
  • Young Yiul Lee
  • Seonyang Park
  • Byoung Kook Kim
Rapid Communication

Abstract

Mutations of nucleophosmin gene (NPM1) are known to be related to good prognosis in AML patients lacking FLT3 internal tandem duplication (FLT3-ITD). Recently, NPM1 mutations other than type A were reported, but their clinical significance is not well known. Retrospective medical record review of 106 de novo AML patients lacking FLT3-ITD, who received induction chemotherapy from three centers in Korea between 1997 and 2007, was performed. Direct sequencing of NPM1 and RT-PCR for FLT3-ITD was performed on genomic DNA derived from blood samples of patients before induction chemotherapy for detection of mutations. NPM1 mutation was detected in 18 patients, where 13 were type A mutants and 5 were non-type A mutants. CR, CR1-D and OS was not different according to NPM1 mutational status overall. But, non-type A NPM1 mutation was related to shorter CR1-D when compared with NPM1 wild types and NPM1 type A mutation (p = 0.004). OS was shorter in non-type A mutants when compared with NPM1 wild-type patients and NPM1 type A mutants (p = 0.001). The type of mutation of NPM1 is important for prognosis in de novo AML lacking FLT3-ITD. Non-A type NPM1 mutation is a poor prognostic factor.

Keywords

AML NPM1 Prognosis 

References

  1. 1.
    Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli MF, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood. 2005;106(12):3733–9. doi:10.1182/blood-2005-06-2248.PubMedCrossRefGoogle Scholar
  2. 2.
    Falini B, Nicoletti I, Martelli MF, Mecucci C. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood. 2007;109(3):874–85. doi:10.1182/blood-2006-07-012252.PubMedCrossRefGoogle Scholar
  3. 3.
    Verhaak RG, Goudswaard CS, van Putten W, Bijl MA, Sanders MA, Hugens W, et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood. 2005;106(12):3747–54. doi:10.1182/blood-2005-05-2168.PubMedCrossRefGoogle Scholar
  4. 4.
    Falini B, Bolli N, Shan J, Martelli MP, Liso A, Pucciarini A, et al. Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. Blood. 2006;107(11):4514–23. doi:10.1182/blood-2005-11-4745.PubMedCrossRefGoogle Scholar
  5. 5.
    Pitiot AS, Santamaria I, Garcia-Suarez O, Centeno I, Astudillo A, Rayon C, et al. A new type of NPM1 gene mutation in AML leading to a C-terminal truncated protein. Leukemia. 2007;21(7):1564–6. doi:10.1038/sj.leu.2404679.PubMedCrossRefGoogle Scholar
  6. 6.
    Wheatley K, Burnett AK, Goldstone AH, Gray RG, Hann IM, Harrison CJ, et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council’s Adult and Childhood Leukaemia Working Parties. Br J Haematol. 1999;107(1):69–79. doi:10.1046/j.1365-2141.1999.01684.x.PubMedCrossRefGoogle Scholar
  7. 7.
    Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96(13):4075–83.PubMedGoogle Scholar
  8. 8.
    Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98(5):1312–20. doi:10.1182/blood.V98.5.1312.PubMedCrossRefGoogle Scholar
  9. 9.
    Don RH, Cox PT, Wainwright BJ, Baker K, Mattick JS. Touchdown’ PCR to circumvent spurious priming during gene amplification. Nucleic Acids Res. 1991;19(14):4008. doi:10.1093/nar/19.14.4008.PubMedCrossRefGoogle Scholar
  10. 10.
    Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005;352(3):254–66. doi:10.1056/NEJMoa041974.PubMedCrossRefGoogle Scholar
  11. 11.
    Kurki S, Peltonen K, Laiho M. Nucleophosmin, HDM2 and p53: players in UV damage incited nucleolar stress response. Cell Cycle. 2004;3(8):976–9.PubMedGoogle Scholar
  12. 12.
    Sherr CJ. Divorcing ARF and p53: an unsettled case. Nat Rev Cancer. 2006;6(9):663–73. doi:10.1038/nrc1954.PubMedCrossRefGoogle Scholar
  13. 13.
    Colombo E, Marine JC, Danovi D, Falini B, Pelicci PG. Nucleophosmin regulates the stability and transcriptional activity of p53. Nat Cell Biol. 2002;4(7):529–33. doi:10.1038/ncb814.PubMedCrossRefGoogle Scholar
  14. 14.
    Suzuki T, Kiyoi H, Ozeki K, Tomita A, Yamaji S, Suzuki R, et al. Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood. 2005;106(8):2854–61. doi:10.1182/blood-2005-04-1733.PubMedCrossRefGoogle Scholar
  15. 15.
    Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 2001;97(8):2434–9. doi:10.1182/blood.V97.8.2434.PubMedCrossRefGoogle Scholar
  16. 16.
    Kang HJ, Hong SH, Kim IH, Park BK, Han KS, Cho HI, et al. Prognostic significance of FLT3 mutations in pediatric non-promyelocytic acute myeloid leukemia. Leuk Res. 2005;29(6):617–23. doi:10.1016/j.leukres.2004.11.006.PubMedCrossRefGoogle Scholar
  17. 17.
    Lee KW, Choi IS, Roh EY, Kim DY, Yun T, Lee DS, et al. Adult patients with t(8;21) acute myeloid leukemia had no superior treatment outcome to those without t(8;21): a single institution’s experience. Ann Hematol. 2004;83(4):218–24. doi:10.1007/s00277-003-0811-1.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2009

Authors and Affiliations

  • Youngil Koh
    • 1
  • Juwon Park
    • 2
  • Eun-Kyung Bae
    • 3
  • Kwang-Sung Ahn
    • 2
  • Inho Kim
    • 1
    • 2
    • 4
  • Soo-Mee Bang
    • 5
  • Jae-Hoon Lee
    • 6
  • Sung-Soo Yoon
    • 1
    • 2
    • 4
  • Dong Soon Lee
    • 7
  • Young Yiul Lee
    • 8
  • Seonyang Park
    • 1
    • 2
    • 4
  • Byoung Kook Kim
    • 1
    • 2
    • 4
  1. 1.Department of Internal MedicineSeoul National University HospitalSeoulRepublic of Korea
  2. 2.Cancer Research InstituteSeoul National University College of MedicineSeoulRepublic of Korea
  3. 3.Department of Biomedical ScienceHanyang University College of MedicineSeoulRepublic of Korea
  4. 4.Clinical Research InstituteSeoul National University HospitalSeoulRepublic of Korea
  5. 5.Department of Internal MedicineSeoul National University Bundang HospitalSeongnamRepublic of Korea
  6. 6.Department of Internal MedicineGachon University College of Medicine Gil HospitalIncheonRepublic of Korea
  7. 7.Department of Clinical PathologySeoul National University HospitalSeoulRepublic of Korea
  8. 8.Department of Internal MedicineHanyang University HospitalSeoulRepublic of Korea

Personalised recommendations